This study showed that tumor-derived MYBL2 transcriptionally activated CCL2 and recruited M2-like macrophages within clinical tumor tissues and model mice, and thus structured the immunosuppressive OVC microenvironment and attenuated the response to anti-PD-1 therapy. This evidence concerns the gene MYBL2 and neoplasm.